References
Key articles
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Full text
Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1.Full text Abstract
Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Full text Abstract
Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
Reference articles
1. Fehm L, Wittchen HU. Comorbidity in social anxiety disorder. In: Bandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:49-63.
2. Stein DJ, Lim CCW, Roest AM, et al. The cross-national epidemiology of social anxiety disorder: data from the World Mental Health Survey Initiative. BMC Med. 2017 Jul 31;15(1):143.Full text Abstract
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
4. Poole KL, Cunningham CE, McHolm AE, et al. Distinguishing selective mutism and social anxiety in children: a multi-method study. Eur Child Adolesc Psychiatry. 2021 Jul;30(7):1059-69. Abstract
5. Szuhany KL, Simon NM. Anxiety disorders: a review. JAMA. 2022 Dec 27;328(24):2431-45. Abstract
6. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602.Full text Abstract
7. Merikangas KR. Vulnerability factors for anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2005 Oct;14(4):649-79;vii. Abstract
8. Asher M, Asnaani A, Aderka IM. Gender differences in social anxiety disorder: a review. Clin Psychol Rev. 2017 Aug;56:1-12. Abstract
9. Busa S, Wernick J, Kellerman J, et al. A descriptive case study of a cognitive behavioral therapy group intervention adaptation for transgender youth with social anxiety disorder. Behav Ther (N Y N Y). 2022 Apr;45(4):135-41.Full text Abstract
10. Bergero-Miguel T, García-Encinas MA, Villena-Jimena A, et al. Gender dysphoria and social anxiety: an exploratory study in Spain. J Sex Med. 2016 Aug;13(8):1270-8. Abstract
11. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. Abstract
12. Carter MM, Mitchell FE, Sbrocco T. Treating ethnic minority adults with anxiety disorders: current status and future recommendations. J Anxiety Disord. 2012 May;26(4):488-501.Full text Abstract
13. Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008 Feb;4(1):123-43.Full text Abstract
14. Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther. 2016 Nov;86:50-67. Abstract
15. Stein MB, Gelernter J, Smoller JW. Genetic aspects of social anxiety and related traits. In: Brandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:197-214.
16. Barlow DH. Anxiety and its disorders, 2nd ed. New York, NY: Guilford Press; 2002.
17. Stein MB, Chen CY, Jain S, et al. Genetic risk variants for social anxiety. Am J Med Genet B Neuropsychiatr Genet. 2017 Mar;174(2):120-31.Full text Abstract
18. Sandstrom A, Uher R, Pavlova B. Prospective association between childhood behavioral inhibition and anxiety: a meta-analysis. J Abnorm Child Psychol. 2020 Jan;48(1):57-66. Abstract
19. Xu J, Ni S, Ran M, et al. The relationship between parenting styles and adolescents' social anxiety in migrant families: a study in Guangdong, China. Front Psychol. 2017 Apr 20:8:626.Full text Abstract
20. Plasencia ML, Alden LE, Taylor CT. Differential effects of safety behaviour subtypes in social anxiety disorder. Behav Res Ther. 2011 Oct;49(10):665-75. Abstract
21. Piccirillo ML, Taylor Dryman M, Heimberg RG. Safety behaviors in adults with social anxiety: review and future directions. Behav Ther. 2016 Sep;47(5):675-87. Abstract
22. Roth DA, Heimberg RG. Cognitive behavioral models of social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):753-71. Abstract
23. Hofmann SG. Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications. Cogn Behav Ther. 2007;36(4):193-209.Full text Abstract
24. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007 Oct;164(10):1476-88.Full text Abstract
25. Freitas-Ferrari MC, Hallak JE, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):565-80. Abstract
26. Schwartz CE, Wright CI, Shin LM, et al. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003 Jun 20;300(5627):1952-3. Abstract
27. Condren RM, O'Neill A, Ryan MC, et al. HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology. 2002 Aug;27(6):693-703. Abstract
28. van West D, Claes S, Sulon J, et al. Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord. 2008 Dec;111(2-3):281-90. Abstract
29. Gelernter J, Page GP, Stein MB, et al. Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry. 2004 Jan;161(1):59-66. Abstract
30. Doehrmann O, Ghosh SS, Polli FE, et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan;70(1):87-97. Abstract
31. Hirshfeld-Becker DR, Micco JA, Simoes NA, et al. High risk studies and developmental antecedents of social anxiety disorder. Am J Med Genet. 2008 May 15;148C(2):99-117. Abstract
32. Aune T, Stiles TC. Universal-based prevention of syndromal and subsyndromal social anxiety: a randomized controlled study. J Consult Clin Psychol. 2009 Oct;77(5):867-79. Abstract
33. Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016 Feb;30(2):128-39.Full text Abstract
34. Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020 Dec 23:11:595584.Full text Abstract
35. Liebowitz, MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992 Apr;49(4):290-300. Abstract
36. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994 Apr;62(2):350-8. Abstract
37. Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981 Mar;169(3):180-4. Abstract
38. Stein MB, Sareen J, Hami S, et al. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 Oct;158(10):1725-7. Abstract
39. Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):603-13.Full text Abstract
40. Wagner R, Silove D, Marnane C, et al. Delays in referral of patients with social phobia, panic disorder, and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006;20(3):363-71. Abstract
41. Canadian Paediatric Society. Position statement: anxiety in children and youth: part 1-diagnosis. Oct 2022 [internet publication].Full text
42. Taylor CT, Laposa JM, Alden LE. Is avoidant personality disorder more than just social avoidance? J Pers Disord. 2004 Dec;18(6):571-94. Abstract
43. Cox BJ, Pagura J, Stein MB, et al. The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress Anxiety. 2009;26(4):354-62. Abstract
44. Lampe L, Malhi GS. Avoidant personality disorder: current insights. Psychol Res Behav Manag. 2018 Mar 8:11:55-66.Full text Abstract
45. Dalrymple K, Martinez J, Tepe E, et al. A clinically useful social anxiety disorder outcome scale. Compr Psychiatry. 2013 Oct;54(7):758-65.Full text Abstract
46. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.Full text Abstract
47. Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: the Liebowitz Social Anxiety Scale. J Anxiety Disord. 2002;16(6):661-73. Abstract
48. Connor K, Kobak KA, Churchill E, et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001;14(2):137-40. Abstract
49. Caporino NE, Sakolsky D, Brodman DM, et al. Establishing clinical cutoffs for response and remission on the screen for child anxiety related emotional disorders (SCARED). J Am Acad Child Adolesc Psychiatry. 2017 Aug;56(8):696-702.Full text Abstract
50. US Preventive Services Task Force. Final recommendation statement: anxiety in children and adolescents: screening. Oct 2022 [internet publication].Full text
51. US Preventive Services Task Force. Final recommendation statement: anxiety disorders in adults: screening. Jun 2023 [internet publication].Full text
52. Gregory KD, Chelmow D, Nelson HD, et al. Screening for anxiety in adolescent and adult women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2020 Jul 7;173(1):48-56. Abstract
53. Runyon K, Chesnut SR, Burley H. Screening for childhood anxiety: a meta-analysis of the screen for child anxiety related emotional disorders. J Affect Disord. 2018 Nov;240:220-9. Abstract
54. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007 Mar 6;146(5):317-25. Abstract
55. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Full text Abstract
56. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. Abstract
57. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003 Aug 1;1:29.Full text Abstract
58. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1107-24.Full text Abstract
59. British Columbia Medical Association Guidelines & Protocols Advisory Committee. Anxiety and depression in children and youth: diagnosis and treatment. July 2024 [internet publication].Full text
60. National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Full text
61. Andrews G, Bell C, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry. 2018;52(12):1109-72.Full text
62. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15.Full text Abstract
63. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1.Full text Abstract
64. Bandelow B, Seidler-Brandler U, Becker A, et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8(3):175-87. Abstract
65. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. part I: anxiety disorders. World J Biol Psychiatry. 2023 Feb;24(2):79-117. Abstract
66. James AC, Reardon T, Soler A, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2020 Nov 16;(11):CD013162.Full text Abstract
67. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 Dec 25;359(26):2753-66.Full text Abstract
68. Ginsburg GS, Kendall PC, Sakolsky D, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011 Dec;79(6):806-13.Full text Abstract
69. Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017 Nov 1;171(11):1049-56.Full text Abstract
70. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-32.Full text Abstract
71. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006 Jan;26(1):17-31. Abstract
72. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Abstract
73. Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Full text Abstract
74. Beidel DC, Ferrell C, Alfano CA, et al. The treatment of childhood social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):831-46. Abstract
75. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001 Jun;21(3):311-24. Abstract
76. Acarturk C, Cuijpers P, van Straten A, et al. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009 Feb;39(2):241-54. Abstract
77. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014 Oct;1(5):368-76.Full text Abstract
78. Barkowski S, Schwartze D, Strauss B, et al. Efficacy of group psychotherapy for social anxiety disorder: a meta-analysis of randomized-controlled trials. J Anxiety Disord. 2016 Apr;39:44-64. Abstract
79. Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Full text Abstract
80. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011 Dec 20;11:200.Full text Abstract
81. Canadian Paediatric Society. Position statement: anxiety in children and youth: part 2 - the management of anxiety disorders. Oct 2022 [internet publication].Full text
82. Scaini S, Belotti R, Ogliari A, et al. A comprehensive meta-analysis of cognitive-behavioral interventions for social anxiety disorder in children and adolescents. J Anxiety Disord. 2016 Aug;42:105-12. Abstract
83. Aderka IM. Factors affecting treatment efficacy in social phobia: the use of video feedback and individual vs. group formats. J Anxiety Disord. 2009 Jan;23(1):12-7. Abstract
84. Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):745-64. Abstract
85. Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disord. 2018 Apr;55:70-8.Full text Abstract
86. National Institute for Health and Care Excellence. Digitally enabled therapies for adults with anxiety disorders: early value assessment. Dec 2023 [internet publication].Full text
87. National Institute for Health and Care Excellence. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment. Sep 2023 [internet publication].Full text
88. Dear BF, Staples LG, Terides MD, et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial. J Anxiety Disord. 2016 Aug;42:30-44.Full text Abstract
89. Hedman E, Andersson G, Ljotsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011 Mar 25;6(3):e18001.Full text Abstract
90. Hedman E, Furmark T, Carlbring P, et al. A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011 Jun 15;13(2):e39.Full text Abstract
91. Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565.Full text Abstract
92. Horigome T, Kurokawa S, Sawada K, et al. Virtual reality exposure therapy for social anxiety disorder: a systematic review and meta-analysis. Psychol Med. 2020 Nov;50(15):2487-97. Abstract
93. Emmelkamp PMG, Meyerbröker K, Morina N. Virtual reality therapy in social anxiety disorder. Curr Psychiatry Rep. 2020 May 13;22(7):32.Full text Abstract
94. Hofmann SG, Gómez AF. Mindfulness-based interventions for anxiety and depression. Psychiatr Clin North Am. 2017 Dec;40(4):739-49.Full text Abstract
95. Hoge EA, Bui E, Mete M, et al. Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21.Full text Abstract
96. Haller H, Breilmann P, Schröter M, et al. A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders. Sci Rep. 2021 Oct 14;11(1):20385.Full text Abstract
97. Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.Full text Abstract
98. Craske MG, Stein MB, Sullivan G, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88.Full text Abstract
99. Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience. Int Rev Psychiatry. 2011 Aug;23(4):318-27.Full text Abstract
100. Gyani A, Shafran R, Layard R, et al. Enhancing recovery rates: lessons from year one of IAPT. Behav Res Ther. 2013 Sep;51(9):597-606.Full text Abstract
101. Wakefield S, Kellett S, Simmonds-Buckley M, et al. Improving Access to Psychological Therapies (IAPT) in the United Kingdom: a systematic review and meta-analysis of 10-years of practice-based evidence. Br J Clin Psychol. 2021 Mar;60(1):1-37.Full text Abstract
102. Baigent M, Smith D, Battersby M, et al. The Australian version of IAPT: clinical outcomes of the multi-site cohort study of NewAccess. J Ment Health. 2020 May 12;1-10. Abstract
103. Knapstad M, Smith ORF. Social anxiety and agoraphobia symptoms effectively treated by Prompt Mental Health Care versus TAU at 6- and 12-month follow-up: secondary analysis from a randomized controlled trial. Depress Anxiety. 2021 Mar;38(3):351-60.Full text Abstract
104. Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Full text Abstract
105. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010 Oct;12(5):471-7. Abstract
106. Roy-Byrne PP, Veitengruber JP, Bystritsky A, et al. Brief intervention for primary care anxiety: a medication focused approach. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.Full text Abstract
107. de Menezes GB, Coutinho ES, Fontenelle LF, et al. Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials. Psychopharmacology (Berl). 2011 May;215(1):1-11. Abstract
108. Kimmel RJ, Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan PE, Gorman JM, eds. A guide to treatments that work. 4th ed. New York, NY: Oxford University Press; 2015:463-506.Full text
109. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002 Jun;22(3):257-62. Abstract
110. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002 Feb;63(2):152-5. Abstract
111. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39. Abstract
112. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013 Jan;28(1):7-20. Abstract
113. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993 Dec;13(6):423-8. Abstract
114. Otto MW, Pollack MH, Gould RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000 Jul-Aug;14(4):345-58. Abstract
115. Davidson JR, Tupler LA, Potts NL. Treatment of social phobia with benzodiazepines. J Clin Psychiatry. 1994 Jun;(suppl 55):28-32. Abstract
116. Kennedy KM, O'Riordan J. Prescribing benzodiazepines in general practice. Br J Gen Pract. 2019 Mar;69(680):152-3.Full text Abstract
117. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004 Feb;65(2):244-8. Abstract
118. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan;171(1):44-53. Abstract
119. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017 Jun;19(2):93-107.Full text Abstract
120. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997;247(2):71-80. Abstract
121. Noyes R, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug;17(4):247-54. Abstract
122. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998 Jan;172:70-7. Abstract
123. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999 Aug;19(4):341-8. Abstract
124. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr;24(2):141-9. Abstract
125. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48. Abstract
126. Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011 Jul;26(4):213-20. Abstract
127. Greist JH, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011 Sep;26(5):243-51. Abstract
128. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977;5(suppl 5):116-23. Abstract
129. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998 Apr;18(2):132-5. Abstract
130. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005 Dec;25(6):580-3. Abstract
131. Davis ML, Smits JA, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin Pharmacother. 2014 Nov;15(16):2281-91. Abstract
132. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017 Sep 25;358:j4461.Full text Abstract
133. Craske MG, Stein MB. Anxiety. Lancet. 2016 Dec 17;388(10063):3048-59. Abstract
134. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998 Oct;18(5):373-8. Abstract
135. Palmer EG, Sornalingam S, Page L, et al. Withdrawing from SSRI antidepressants: advice for primary care. Br J Gen Pract. 2023 Mar;73(728):138-40.Full text Abstract
136. National Institute for Health and Care Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. Apr 2022 [internet publication].Full text
137. Haug T, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003 Apr;182:312-8.Full text Abstract
138. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992 Apr;49(4):282-8. Abstract
139. Kessler KC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998 May;155(5):613-9.Full text Abstract
140. Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
141. Feldman G. Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. Psychiatr Clin North Am. 2007 Mar;30(1):39-50. Abstract
142. Ott CA. Treatment of anxiety disorders in patients with comorbid bipolar disorder. Ment Health Clin. 2018 Nov;8(6):256-63.Full text Abstract
143. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111. Abstract
144. Liebowitz MB, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005 Feb;62(2):190-8.Full text Abstract
145. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002 Dec;16(4):365-8. Abstract
146. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry. 2005 Apr;66(4):540-2. Abstract
147. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008120.Full text Abstract
148. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996 Jul 8;39(2):115-21. Abstract
149. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 Mar 15;63(6):544-9. Abstract
150. Tolin DF, Lord KA, Knowles KA. Cognitive-behavioral therapy enhancement strategies. Psychiatr Clin North Am. 2024 Jun;47(2):355-65. Abstract
151. Mataix-Cols D, Fernández de la Cruz L, Monzani B, et al. D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017 May 1;74(5):501-10.Full text Abstract
152. Smits JAJ, Pollack MH, Rosenfield D, et al. Dose timing of D-cycloserine to augment exposure therapy for social anxiety disorder: a randomized clinical trial. JAMA Netw Open. 2020 Jun 1;3(6):e206777.Full text Abstract
153. Pelissolo A, Abou Kassm S, Delhay L. Therapeutic strategies for social anxiety disorder: where are we now? Expert Rev Neurother. 2019 Dec;19(12):1179-89. Abstract
154. Hertenstein E, Trinca E, Schneider CL, et al. Augmentation of psychotherapy with neurobiological methods: current state and future directions. Neuropsychobiology. 2021;80(6):437-53.Full text Abstract
155. Markowitz JC, Lipsitz J, Milrod BL. Critical review of outcome research on interpersonal psychotherapy for anxiety disorders. Depress Anxiety. 2014 Apr;31(4):316-25.Full text Abstract
156. Tang L, Xu F, Yu G, et al. Efficacy of interpersonal psychotherapy in mainland China: a systematic review and meta-analysis. Front Psychiatry. 2023 Jul 12:14:1160081.Full text Abstract
157. Amir N, Bomyea J, Beard C. The effect of single-session interpretation modification on attention bias in socially anxious individuals. J Anxiety Disord. 2010 Mar;24(2):178-82.Full text Abstract
158. Liu H, Li X, Han B, et al. Effects of cognitive bias modification on social anxiety: a meta-analysis. PLoS One. 017 Apr 6;12(4):e0175107.Full text Abstract
159. Norton PJ, Barrera TL. Transdiagnostic versus diagnosis-specific CBT for anxiety disorders: a preliminary randomized controlled noninferiority trial. Depress Anxiety. 2012 Oct;29(10):874-82.Full text Abstract
160. Ito M, Horikoshi M, Kato N, et al. Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial. Psychol Med. 2023 May;53(7):3009-20.Full text Abstract
161. Barlow DH, Farchione TJ, Bullis JR, et al. The unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: a randomized clinical trial. JAMA Psychiatry. 2017 Sep 1;74(9):875-84.Full text Abstract
162. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014 Feb;48(3):187-96. Abstract
163. Zika MA, Becker L. Physical activity as a treatment for social anxiety in clinical and non-clinical populations: a systematic review and three meta-analyses for different study designs. Front Hum Neurosci. 2021 Jun 11:15:653108.Full text Abstract
164. Griffiths C, da Silva K, Jiang H, et al. Alpha-Stim AID cranial electrotherapy stimulation (CES) anxiety treatment: anxiety, depression and health-related quality-of-life outcomes in primary health-care social prescribing services. Ment Health Rev J. 2023 May 25;28(4):337-49.Full text
165. National Institute for Health and Care Excellence. Alpha-stim AID for anxiety disorders. Mar 2021 [internet publication].Full text
166. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40. Abstract
167. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
168. US Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2007 [internet publication].
170. Reisman Y. Sexual Consequences of post-SSRI syndrome. Sex Med Rev. 2017 Oct;5(4):429-33. Abstract
171. Krause KR, Chung S, Adewuya AO, et al. International consensus on a standard set of outcome measures for child and youth anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder. Lancet Psychiatry. 2021 Jan;8(1):76-86. Abstract
Use of this content is subject to our disclaimer